Articles with public access mandates - Won Jin HoLearn more
Not available anywhere: 1
Pembrolizumab for the treatment of head and neck squamous cell cancer
WJ Ho, R Mehra
Expert Opinion on Biological Therapy 19 (9), 879-885, 2019
Mandates: US National Institutes of Health
Available somewhere: 34
The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities
WJ Ho, EM Jaffee, L Zheng
Nature reviews Clinical oncology 17 (9), 527-540, 2020
Mandates: US National Institutes of Health
Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival
L Danilova, WJ Ho, Q Zhu, T Vithayathil, A De Jesus-Acosta, NS Azad, ...
Cancer immunology research 7 (6), 886-895, 2019
Mandates: US National Institutes of Health
Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
WJ Ho, M Yarchoan, A Hopkins, R Mehra, S Grossman, H Kang
Journal for immunotherapy of cancer 6, 1-8, 2018
Mandates: US National Institutes of Health
A phase II study of allogeneic GM-CSF–transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer
AA Wu, KM Bever, WJ Ho, EJ Fertig, N Niu, L Zheng, RM Parkinson, ...
Clinical cancer research 26 (19), 5129-5139, 2020
Mandates: US National Institutes of Health
From bench to bedside: Single-cell analysis for cancer immunotherapy
EF Davis-Marcisak, A Deshpande, GL Stein-O’Brien, WJ Ho, D Laheru, ...
Cancer cell 39 (8), 1062-1080, 2021
Mandates: US National Institutes of Health
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ...
Nature Cancer 2 (9), 891-903, 2021
Mandates: US National Institutes of Health
Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes
A Balaji, J Zhang, B Wills, KA Marrone, H Elmariah, M Yarchoan, ...
Journal of oncology practice 15 (9), e825-e834, 2019
Mandates: US National Institutes of Health
Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
WJ Ho, L Danilova, SJ Lim, R Verma, S Xavier, JM Leatherman, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
Multi-scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
H Mi, WJ Ho, M Yarchoan, AS Popel
Frontiers in Immunology, 1986, 2022
Mandates: US National Institutes of Health
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
WJ Ho, R Erbe, L Danilova, Z Phyo, E Bigelow, G Stein-O’Brien, ...
Genome biology 22 (1), 154, 2021
Mandates: US National Institutes of Health
Systemic inhibition of PTPN22 augments anticancer immunity
WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ...
The Journal of Clinical Investigation 131 (17), 2021
Mandates: US National Institutes of Health, Susan G. Komen
Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort
WJ Ho, MS Simon, VO Yildiz, JM Shikany, I Kato, JL Beebe‐Dimmer, ...
Cancer 121 (4), 580-588, 2015
Mandates: US National Institutes of Health
Effects of B cell–activating factor on tumor immunity
M Yarchoan, WJ Ho, A Mohan, Y Shah, T Vithayathil, J Leatherman, ...
JCI insight 5 (10), 2020
Mandates: US National Institutes of Health
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments
DJ Zabransky, L Danilova, JM Leatherman, TY Lopez‐Vidal, J Sanchez, ...
Hepatology 77 (5), 1566-1579, 2023
Mandates: US National Institutes of Health
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
RJ Sové, BK Verma, H Wang, WJ Ho, M Yarchoan, AS Popel
Journal for immunotherapy of cancer 10 (11), 2022
Mandates: US National Institutes of Health
Macrophage-targeting by CSF1/1R blockade in pancreatic cancers
WJ Ho, EM Jaffee
Cancer research 81 (24), 6071-6073, 2021
Mandates: US National Institutes of Health
Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes
WJ Ho, M Yarchoan, S Charmsaz, RM Munday, L Danilova, MB Sztein, ...
JCI insight 5 (2), 2020
Mandates: US National Institutes of Health
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
WJ Ho, G Sharma, Q Zhu, G Stein-O'Brien, J Durham, R Anders, ...
Journal for immunotherapy of cancer 8 (2), 2020
Mandates: US National Institutes of Health
Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces
A Deshpande, M Loth, DN Sidiropoulos, S Zhang, L Yuan, ATF Bell, ...
Cell systems 14 (4), 285-301. e4, 2023
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program